LLY ELI LILLY & Co
What matters nowUpdated 3 h ago
- The latest development is the FDA approval of Jaypirca as a first-line treatment for untreated CLL or SLL on October 2, 2026, which extends the BTK inhibitor into frontline use 1; on October 9 Lilly reported exploratory TOGETHER-PsO data showing broader psoriasis and metabolic biomarker changes with Taltz plus Zepbound than with Taltz alone 2.
- The pooled 24/7 venue price of LLY is 1,176.81 USD, down 0.53% from the previous close of 1,183.07 USD, with a market cap of about 1.11 trillion USD and a P/E of 39.5. Recent pipeline news includes the EloraTZP Phase 2b combination of eloralintide and tirzepatide, which produced up to 23.3% weight loss at 48 weeks against 14.8% with tirzepatide 15 mg 3, and retatrutide TRIUMPH-2 detail showing 20.8% weight loss at 12 mg, published in The Lancet 4.
- Foundayo, the oral GLP-1 approved for obesity on April 1, 2026, met non-inferiority against insulin glargine on major adverse cardiovascular events in ACHIEVE-4, although the point estimates favored Foundayo and the confidence intervals include no difference 5; the FDA approved the once-weekly basal insulin Onswik for type 2 diabetes on September 24, 2026 6.
- Trailing twelve-month revenue is 79.67 billion USD, up 49.6% year on year, with EPS of 29.80 USD up 94.8%, a gross margin of 83.4% and a net margin of 33.5% (as of June 30, 2026); net debt is 45.96 billion USD. Insiders sold 31,828 shares worth 34.6 million USD over the last 180 days across five sales, four of them planned, and bought none.
- Next up is the Q3 2026 earnings call on October 29, 2026 at 14:00 UTC (not yet confirmed), and the US September CPI release on October 14 at 12:30 UTC. Retatrutide's BLA submission to the FDA is planned for Q1 2027 4. Polymarket prices an 81.5% chance of no change in Fed rates after the October 2026 meeting and 17.5% for a 25 bp increase.
Eli Lilly press release · Oct 2
Eli Lilly press release · Oct 9
Eli Lilly press release · Sep 30
Eli Lilly press release · Sep 29
Eli Lilly press release (PR Newswire) · Sep 30
Healio · Sep 24
Valuation & fundamentalsFull financials →
TTM through 2026-06-30 from SEC filings (some quarters derived from annual and year-to-date figures). Ratios use our pooled 24/7 price. Quarterly statements →
Every venue
| Venue | Price | vs pool | 24h vol | Open int. | Funding 8h |
|---|---|---|---|---|---|
| binance perp LLYUSDT · just now | 1,166.48 | +0.01% | $2.9M | $2.3M | 0.0000% |
| hyperliquid perp xyz:LLY · just now | 1,164.25 | −0.18% | $514.1K | $4.7M | 0.0050% |
| bitget perp LLYUSDT · just now | 1,166.93 | +0.05% | $465.8K | $2.4M | 0.0256% |
| okx perp LLY-USDT-SWAP · just now | 1,164.40 | −0.17% | $332.1K | $662.4K | 0.0000% |
| bybit perp LLYUSDT · just now | 1,166.66 | +0.03% | $164.0K | $1.5M | 0.0000% |
| aster perp LLYUSDT · just now | 1,165.82 | −0.04% | $20.2K | $22.0K | 0.0035% |
Pooled price = volume-weighted median of venues within 2% of each other. Venue markets for stocks, indices and gold are 24/7 perpetual contracts; they track but are not the official exchange price.
Open interest, 120 days
US$ millions, all venues
Funding, 120 days
Annualised %, OI-weighted. Positive: longs pay shorts.
NewsAll news →
Taltz plus Zepbound shows broader biomarker changes than Taltz alone in psoriasis
On October 9, 2026 Lilly reported exploratory biomarker data from the TOGETHER-PsO Phase 3b trial, presented at Fall Clinical Dermatology.
Lilly presents 21 dermatology presentations at Fall Clinical 2026
Lilly announced on October 5, 2026 that it would present 21 dermatology presentations at the Fall Clinical Dermatology Conference in Las Vegas, held October 8-11.
FDA approves Jaypirca as first-line treatment for untreated CLL/SLL
The FDA approved Jaypirca (pirtobrutinib) on October 2, 2026 as a first-line treatment for adults with previously untreated CLL or SLL who do not have a 17p deletion.
EloraTZP Phase 2b: eloralintide plus tirzepatide beats tirzepatide 15 mg
Lilly reported Phase 2b results for EloraTZP, a combination of its amylin agonist eloralintide and tirzepatide, on September 30, 2026.
Foundayo ACHIEVE-4: MACE-4 non-inferiority met vs insulin glargine, not significant
Lilly reported detailed ACHIEVE-4 results for Foundayo on September 30, 2026, showing the oral GLP-1 met non-inferiority against insulin glargine on major adverse cardiovascular events.
Retatrutide TRIUMPH-2 detail: 20.8% weight loss at 12 mg, published in The Lancet
Lilly presented detailed TRIUMPH-2 results for retatrutide at the EASD meeting in Milan on September 29, 2026, with a simultaneous Lancet publication.
FDA approves Onswik, Lilly's once-weekly basal insulin for type 2 diabetes
The FDA approved insulin efsitora alfa-gobe, sold as Onswik, on September 24, 2026 as a once-weekly basal insulin for adults with type 2 diabetes.
Lilly completes acquisition of AtaiBeckley
Lilly announced on September 11, 2026 that it had completed its acquisition of AtaiBeckley, after the target's shareholders approved the transaction.
Lilly agrees to acquire Merida Biosciences for up to $2.875B in cash
Lilly signed a definitive agreement on August 31, 2026 to acquire Merida Biosciences, a Cambridge, Massachusetts biotech, for up to $2.875 billion in cash including milestones.
UK MHRA approves Foundayo (orforglipron) for weight management and type 2 diabetes
The UK Medicines and Healthcare products Regulatory Agency authorised Lilly's oral GLP-1 Foundayo for weight management and for type 2 diabetes on August 10, 2026.
Lilly Q2 2026 revenue rises 48% to $22.97B; 2026 revenue guidance raised to $85-87B
Lilly reported second-quarter 2026 revenue of $22,974 million, up 48%, driven by volume growth of 60% that more than offset a 13% drop in realized prices.
Retatrutide Phase 3 TRIUMPH-2 and TRIUMPH-3 positive; up to 22.6% weight loss
Lilly reported positive topline results from two Phase 3 trials of retatrutide, its triple GIP, GLP-1 and glucagon agonist.
Retatrutide meets primary endpoints in TRIUMPH-2 and TRIUMPH-3
Lilly reported that retatrutide met the primary endpoint in two more Phase 3 obesity trials: TRIUMPH-2 in adults with obesity and type 2 diabetes, and TRIUMPH-3 in adults with severe obesity and cardiovascular disease.
Lilly agrees to buy AtaiBeckley in all-cash deal worth up to $3.8B
Lilly agreed to acquire the clinical-stage psychedelic medicines company AtaiBeckley for up to $3.8 billion in cash.
Medicare GLP-1 Bridge starts July 1 with $50 monthly copay for Zepbound and Foundayo
Eligible Medicare Part D patients can get Zepbound and Foundayo for weight management for $50 a month under the Medicare GLP-1 Bridge program, which started July 1, 2026.